Disc Medicine: RALLY-MF Data Validates Pipeline Optionality [Seeking Alpha]
Disc Medicine, Inc. (IRON)
Company Research
Source: Seeking Alpha
Bitopertin's NDA is submitted, aiming for accelerated FDA approval; if successful, IRON transitions from R&D to commercial stage with significant revenue potential. Phase 2 data for DISC-0974 in myelofibrosis show strong efficacy, especially in synergy with JAK inhibitors, expanding the addressable market and clinical utility. Key risks include regulatory uncertainty for bitopertin's accelerated approval and challenges in patient identification for rare disease commercialization. J Studios/DigitalVision via Getty Images My bullish outlook for Disc Medicine ( IRON ) is based on the fact that the company has structured itself out of the classic problem research-stage biotechs face, where they have promising candidates but are cash-strapped This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myse
Show less
Read more
Impact Snapshot
Event Time:
IRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRON alerts
High impacting Disc Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
IRON
News
- Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer [Yahoo! Finance]Yahoo! Finance
- Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources OfficerGlobeNewswire
- Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026GlobeNewswire
- What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run [Yahoo! Finance]Yahoo! Finance
- Disc Medicine (NASDAQ:IRON) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
IRON
Earnings
- 11/6/25 - Miss
IRON
Sec Filings
- 1/12/26 - Form 8-K
- 1/7/26 - Form SCHEDULE
- 1/5/26 - Form 4
- IRON's page on the SEC website